| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2008 | 2007 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 6,1 M € | -26.6% | 8,3 M € | +40.7% | 5,9 M € | -46.5% | 11,0 M € | +13.5% | 9,7 M € | +30.8% | 7,4 M € | -53.8% | 16,0 M € | +91.5% | 8,3 M € | — | — | ||||||
| Gross margin | -217,0 k € | -135.6% | 609,5 k € | -70.0% | 2,0 M € | — | — | — | — | — | — | — | — | — | — | |||||||||||
| EBITDA | -218,2 k € | +92.5% | -2,9 M € | -2176.7% | -128,4 k € | -196.3% | 133,3 k € | -85.7% | 934,9 k € | +202.7% | -910,8 k € | +59.5% | -2,2 M € | -10.7% | -2,0 M € | -8.1% | -1,9 M € | -120.3% | 9,3 M € | +115.9% | 4,3 M € | +144.4% | -9,7 M € | -48.8% | -6,5 M € | |
| Operating profit | -218,2 k € | +92.6% | -3,0 M € | -1075.3% | -251,1 k € | -178.2% | -90,3 k € | -114.8% | 609,4 k € | +143.0% | -1,4 M € | +49.3% | -2,8 M € | -11.4% | -2,5 M € | -11.6% | -2,2 M € | -125.4% | 8,9 M € | +122.8% | 4,0 M € | +139.1% | -10,2 M € | -43.0% | -7,1 M € | |
| Profit/loss | -372,2 k € | +85.2% | -2,5 M € | -1321.4% | 206,4 k € | -73.1% | 766,0 k € | -18.5% | 939,5 k € | +142.6% | -2,2 M € | +5.9% | -2,3 M € | +5.1% | -2,5 M € | +19.2% | -3,1 M € | -134.0% | 9,0 M € | +128.7% | 3,9 M € | +139.3% | -10,0 M € | -43.9% | -7,0 M € | |
| Equity | 8,6 M € | -4.2% | 9,0 M € | -21.9% | 11,5 M € | +1.8% | 11,3 M € | +7.3% | 10,5 M € | +9.8% | 9,6 M € | -18.7% | 11,8 M € | -16.6% | 14,1 M € | -14.9% | 16,6 M € | -15.5% | 19,6 M € | +84.3% | 10,7 M € | -13.3% | 12,3 M € | +132.5% | 5,3 M € | |
| Total assets | 8,8 M € | -10.4% | 9,8 M € | -23.6% | 12,8 M € | -2.5% | 13,1 M € | +2.5% | 12,8 M € | +8.0% | 11,8 M € | -15.5% | 14,0 M € | -15.6% | 16,6 M € | -8.5% | 18,1 M € | -16.6% | 21,8 M € | +71.5% | 12,7 M € | -11.2% | 14,3 M € | +123.4% | 6,4 M € | |
| Cash | 71,0 k € | +111.5% | 33,5 k € | -92.6% | 453,0 k € | +30.4% | 347,2 k € | -65.7% | 1,0 M € | -46.6% | 1,9 M € | +42.8% | 1,3 M € | +232.7% | 399,0 k € | -80.9% | 2,1 M € | -63.4% | 5,7 M € | +108.4% | 2,7 M € | +318.0% | 654,1 k € | +83.0% | 357,5 k € | |
| Debts | 160,7 k € | +47.8% | 108,7 k € | -91.7% | 1,3 M € | -10.1% | 1,5 M € | -20.9% | 1,8 M € | -18.5% | 2,3 M € | +1.1% | 2,2 M € | +4.3% | 2,2 M € | +38.1% | 1,6 M € | +25.1% | 1,2 M € | +27.3% | 977,2 k € | -30.4% | 1,4 M € | +52.6% | 920,0 k € | |
| Staff | — | 10,9 | 17,2 | 18,6 | 16,5 | 16,1 | 31,6 | 32,2 | 29,2 | 22,5 | 18,7 | 34,6 | 18,8 | |||||||||||||
Public limited company · Nazareth-De Pinte · incorporated on 03/07/2006
Public limited company loss-making in the latest fiscal year. Cash position rising (+111.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Intrexon Actobiotics is a Public limited company incorporated in 2006. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Nazareth-De Pinte.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette